Expertise in
10
conditions

Andrew N. Davies

Guy's And St Thomas' NHS Trust, 
London, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
10
conditions
Guy's And St Thomas' NHS Trust, 
London, ENG, GB 

Overview

Andrew Davies practices practicing medicine in London, United Kingdom.

Mr. Davies is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Opioid Induced Constipation, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Vitrectomy, and Gastrectomy.

He is actively involved in clinical research, co-authoring 305 peer reviewed articles and participating in 8 clinical trials.

Gender

Male

Locations

Guy's And St Thomas' NHS Trust, London, ENG, United Kingdom
Other Locations
University of Rhode Island
Kingston, RI

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.
Enrollment Status: Recruiting
Publish Date: December 18, 2025
Intervention Type: Drug
Study Drug: CCS1477
Study Phase: Phase 1/Phase 2
IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2026
Intervention Type: Radiation, Other
Study Phase: Not Applicable
An International Phase II Trial Assessing Tolerability and Efficacy of Sequential Methotrexate-Aracytin-based Combination and R-ICE Combination, Followed by HD Chemotherapy Supported by ASCT, in Patients With Systemic B-cell Lymphoma With CNS Involvement at Diagnosis or Relapse (MARIETTA Regimen)
An International Phase II Trial Assessing Tolerability and Efficacy of Sequential Methotrexate-Aracytin-based Combination and R-ICE Combination, Followed by HD Chemotherapy Supported by ASCT, in Patients With Systemic B-cell Lymphoma With CNS Involvement at Diagnosis or Relapse (MARIETTA Regimen)
Enrollment Status: Completed
Publish Date: July 08, 2025
Intervention Type: Drug, Radiation
Study Drugs: Methotrexate, Rituximab, Cytarabine, Thiotepa, Liposomal Cytarabine, Etoposide, Ifosfamide, Carmustine
Study Phase: Phase 2
An Observational Study of Diagnostic Criteria, Clinical Features and Management of Opioid Induced Constipation (OIC) in European Patients With Cancer Pain
An Observational Study of Diagnostic Criteria, Clinical Features and Management of Opioid Induced Constipation (OIC) in European Patients With Cancer Pain
Enrollment Status: Completed
Publish Date: April 03, 2025
Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts
Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts
Enrollment Status: Terminated
Publish Date: October 24, 2024
Intervention Type: Biological
Study Drug: GEN3009
Study Phase: Phase 1/Phase 2
Phase I/II Study to Determine the Maximum Tolerated Dose and Activity of the Combination of Romidepsin and Carfilzomib in Relapsed or Refractory Peripheral T-cell Lymphoma
Phase I/II Study to Determine the Maximum Tolerated Dose and Activity of the Combination of Romidepsin and Carfilzomib in Relapsed or Refractory Peripheral T-cell Lymphoma
Enrollment Status: Completed
Publish Date: May 18, 2022
Intervention Type: Drug
Study Drugs: Romidepsin, Carfilzomib
Study Phase: Phase 1/Phase 2
Torch: A Phase II Study to Determine the Safety and Efficacy of the Dual mTORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Torch: A Phase II Study to Determine the Safety and Efficacy of the Dual mTORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Enrollment Status: Completed
Publish Date: November 05, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Feasibility Study of the Use of Actigraphy to Determine Prognosis in Patients With Advanced Cancer
A Feasibility Study of the Use of Actigraphy to Determine Prognosis in Patients With Advanced Cancer
Enrollment Status: Completed
Publish Date: March 28, 2019
View 7 Less Clinical Trials

305 Total Publications

REstoring Sleep and Energy using a mulTimodal non-pharmacological intervention in advanced Cancer: A feasibility study (RESET-C).
REstoring Sleep and Energy using a mulTimodal non-pharmacological intervention in advanced Cancer: A feasibility study (RESET-C).
Journal: Palliative medicine
Published: March 24, 2026

Frequently Asked Questions about Andrew N. Davies

Is Andrew N. Davies a top-rated expert for Opioid Induced Constipation?

MediFind is an objective health platform that identifies experts based on real-world data. Andrew N. Davies is classified as an Distinguished expert for Opioid Induced Constipation, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Andrew N. Davies participate in research or clinical trials?

Yes. Andrew N. Davies has published 305 articles and abstracts on conditions like Opioid Induced Constipation. You can view a list of Andrew N. Davies's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Davies's expertise for a condition
ConditionClose
    View All 37 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile